‘Jardiance’ challenges first cardiovascular disease prevention as antidiabetic

‘Jardiance’ challenges to secure the ‘cardiovascular disease prevention’ indication for the first time as a diabetes drug.

According to the industry concerned on the 27^th, Boehringer Ingelheim and Lilly turned in application of indication extension over cardiovascular risk reduction to the Ministry of Food and Drug Safety, at the same time in the U.S.

This was based on the ‘Empa-Reg Outcome’ ...